文献速递肝病消化道肿瘤与早癌消化内镜

慢性肝病与更早期胆管癌诊断及预后改善相关:GLOBAL-BTC注册研究

Chronic liver disease is associated with earlier-stage cholangiocarcinoma diagnosis and improved prognosis: Findings from the GLOBAL-BTC registry.
PubMed 文献 · J Hepatol · 2026-08-24

该国际多中心回顾性研究分析2010至2024年3743例胆管癌患者,比较合并与不合并慢性肝病者的临床特征和生存。慢性肝病组更常为肝内胆管癌、分期更早、接受根治性手术更多,总生存和5年生存更优,尤其在肝内胆管癌亚组。

要点

  • 慢性肝病胆管癌患者更常表现为肝内肿瘤且分期更早。
  • 慢性肝病组接受根治性手术比例更高,中位总生存更长。
  • 肝内胆管癌亚组中慢性肝病的生存获益更明显。

核心结论

  • 合并慢性肝病的胆管癌患者诊断分期更早且生存改善,支持在高危慢性肝病人群中实施结构化监测。

研究设计与样本

  • 国际多中心回顾性分析2010至2024年确诊的3743例胆管癌患者,慢性肝病定义为有原发性硬化性胆管炎、肝硬化、病毒性肝炎或其他慢性肝病记录。

主要发现

  • 慢性肝病组993例,非慢性肝病组2750例;慢性肝病组男性67%对53%,中位年龄63对66岁。
  • 慢性肝病组肝内肿瘤64%对42%,ECOG 0为53%对35%,CA19.9为56对135 U/mL。
  • 慢性肝病组局限期57%对43%,转移期23%对31%。
  • 倾向评分匹配后慢性肝病组诊断分期更早,根治性手术60%对48%。
  • 慢性肝病组中位总生存12.2对11.1个月(HR 0.88,95%CI 0.80-0.98),5年生存OR 1.70(95%CI 1.37-2.11)。

关键数值与推荐

  • 慢性肝病定义包括原发性硬化性胆管炎、肝硬化、病毒性肝炎或其他慢性肝病记录。
  • 慢性肝病组与非慢性肝病组各治疗方式的治疗反应相当。

临床怎么用

  • 对高风险慢性肝病人群可考虑结构化胆管癌监测以促进早期诊断。
  • 慢性肝病患者确诊胆管癌后更应评估根治性手术机会。
  • 需前瞻性评估监测策略的临床效用、成本效益及非侵入性生物标志物的优化。

局限性

  • 本研究为回顾性分析,原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Cholangiocarcinoma (CCA) is an aggressive cancer with rising incidence and mortality worldwide. Chronic liver disease (CLD) is a well-recognized risk factor, but its influence on tumor presentation and clinical outcomes remains unclear. We aimed to compare the clinical course of CCA in patients with and without CLD. METHODS: We retrospectively analyzed 3,743 patients diagnosed with CCA between 2010 and 2024 across international centers. CLD was defined by documented primary sclerosing cholangitis, cirrhosis, viral hepatitis, or other chronic liver disorders; remaining patients were classified as non-CLD. Demographic, clinical, biochemical, treatment, and survival features were compared. RESULTS: Among the CCA cohort, 993 patients had CLD. Compared with non-CLD patients (n=2,750), those with CLD were more frequently male (67% vs. 53%) and younger (median age 63 vs. 66 years). CLD-CCA patients more often presented with intrahepatic tumors (64% vs. 42%), better performance status (ECOG 0: 53% vs. 35%), lower CA19.9 levels (56 vs. 135 U/mL), and earlier-stage disease (localized: 57% vs. 43%; metastatic: 23% vs. 31%). In propensity score-matched analyses, patients with prior CLD were diagnosed at earlier CCA stages than non-CLD controls. Consequently, curative-intent tumor surgery was performed more frequently in CLD patients (60% vs. 48%), resulting into longer median overall survival (mOS 12.2 vs. 11.1 months; HR 0.88, 95%CI 0.80-0.98) and higher 5-year survival (OR 1.70, 95%CI 1.37-2.11), particularly in intrahepatic CCA (mOS: 14.2 vs. 11.1 months; HR 0.77, 95%CI 0.68-0.87; 5-year survival OR 2.19, 95%CI 1.60-3.01). Treatment responses across modalities were comparable between groups. CONCLUSION: Pre-existing CLD is associated with earlier-stage CCA diagnosis and improved survival, supporting the implementation of structured surveillance strategies in high-risk CLD populations. IMPACT AND IMPLICATIONS: This international multicenter study show that pre-existing CLD is associated with earlier-stage CCA diagnosis, likely due to closer clinical surveillance, greater eligibility for curative-intent surgery, and improved survival. Treatment responses were similar regardless of CLD status. These findings support established surveillance in high-risk groups and highlight the need to optimize strategies for selected moderate-to-high risk CLD populations, alongside prospective evaluation of their clinical utility, cost-effectiveness, and potential refinement through more accurate non-invasive biomarkers.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Izquierdo-Sanchez L, Narbaiza J, Martin-Robles J, et al. Chronic liver disease is associated with earlier-stage cholangiocarcinoma diagnosis and improved prognosis: Findings from the GLOBAL-BTC registry. J Hepatol. 2026. PMID: 42637053. doi:10.1016/j.jhep.2026.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。